Quantose™ IR is a laboratory developed test (LDT) that measures Insulin Resistance in a patient and is the first and only LDT for determining Insulin Resistance that was developed and validated against the hyperinsulinemic euglycemic clamp, the gold standard for insulin sensitivity.
Quantose™ IR provides an easily understood score – based on a panel of non-glycemic biomarkers – that may be used to determine if a patient is insulin resistant, which may indicate a higher risk of Insulin Resistance-related conditions, such as Type 2 Diabetes, obesity, cardiovascular disease, and hypertension.
Why is measuring Insulin Resistance important?
- Insulin Resistance can be present more than 10 years prior to any changes in glycemic measures making it one of the early signs of prediabetes, diabetes and cardiovascular disease1,2
- Patients with Insulin Resistance are 3-4 times more likely to progress to Type 2 Diabetes within 5 years3
- “If we found prediabetes and early diabetes when they first presented and treated them more effectively, we could prevent or delay the progression of hyperglycemia and the development of complications.”4
- Current approaches diagnose prediabetes/diabetes when 70-80% beta cell function has already been lost5
1Martin, 1992, Warram 1990
2Facchini et al J.Clin. Endocrinol. Metab. 2001; 86:3574
3Data on file at Metabolon
4Phillips, Ratner, Buse & Kahn, We Can Change the Natural History of Type 2 Diabetes, Diabetes Care, Oct 2014
5DeFronzo, Diabetes Care 2011
How could the Quantose™ IR test help in my practice?
- Insulin Resistance is a known risk factor for prediabetes, diabetes, and cardiovascular disease1
- Researchers believe if prediabetes and early diabetes were found in the first 10 years of their natural history, when the disorder is easiest to treat, progression of hyperglycemia and the development of complications could be prevented or delayed.2
- Quantose™IR :
- Can identify Insulin Resistance before changes in glucose are detected by current tests
- Stratifies patients based on a higher risk of disease progression
- Provides a measure for changes in insulin sensitivity
- May aid in assessing the effectiveness of preventative measures and/or pharmacologic interventions
1Reaven G. Diabetes 1988; 37:1595
2Phillips, Ratner, Buse & Kahn, We Can Change the Natural History of Type 2 Diabetes, Diabetes Care, Oct 2014
Who are the appropriate patients for the Quantose™IR test?
Appropriate patients for the Quantose™ IR test are:
- Those at risk of developing Type 2 Diabetes as identified by the ADA Guidelines
- Insulin Resistant and are being assessed for their response to therapy and/or lifestyle changes
- Overweight or obese
- Have other risk factors including hypertension, family history, or certain ethnic groups – African American, Latino, Native American, Asian American, and Pacific Islander
How often should I use the Quantose™ IR test to assess my patient for Insulin Resistance?
- Patients testing positive for Insulin Resistance by Quantose™ IR and who have been placed on weight loss treatment – follow-up testing should be conducted post treatment once the patient’s weight has stabilized – usually 6 months post intervention after the weight loss has stabilized
- Patients testing negative for Insulin Resistance by Quantose™ IR, but whom continue to have risk factors associated with the development of Type 2 Diabetes and cardiovascular disease – testing along with traditional glycemic markers is suggested every 12-24 months at discretion of physician.
How are the test results reported?
Results are provided directly to the healthcare professional by the laboratory who performed the test.
How can I implement the Quantose™ IR test in my practice?
Contact Metabolon at 1.844.IR.FIRST (1.844.473.4778) or email us at QuantoseIR@metabolon.com.